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Abstract
Background
Estimating the current global prevalence of metabolic syndrome (MetS), and its compo-
nents, among rheumatoid arthritis (RA) patients is necessary in order to formulate preventa-
tive strategies and to ensure there are adequate community resources available for these
patients. Furthermore, the association between RA and MetS is controversial and has not
previously been comprehensively assessed. Therefore, the present study aimed to: 1)
determine the prevalence of MetS, and its components, among RA patients across the
world 2) update the odds ratio of MetS in RA patients, compared to healthy controls, using a
comprehensive systematic review and meta-analysis.
Methods
International databases, including: the Web of Science, PubMed, Scopus, Embase,
CINAHL and other relevant databases were searched to identify English language articles
which reported the prevalence and risk of MetS in RA patients between January 2000 and
August 2016. The meta-analysis only included studies which clearly described the time and
location of the study, utilised adequate sampling strategies, and appropriate statistical
analyses.
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Results
The meta-analyses of prevalence (70 studies [n = 12612]) and risk (43 studies [n = 35220])
of MetS in RA patients were undertaken separately. The overall pooled prevalence of MetS
was 30.65% (95% CI: 27.87–33.43), but this varied from 14.32% (95% CI: 10.59–18.05) to
37.83% (95% CI: 31.05–44.61), based upon the diagnostic criteria used. The prevalence of
MetS also varied slightly between males (31.94%, 95% CI: 24.37–39.51) and females
(33.03%, 95% CI: 28.09–37.97), but this was not statistically significant. The overall pooled
odds ratio (OR) of MetS in RA patients, compared to healthy controls, was 1.44 (95% CI:
1.20–1.74), but this ranged from 0.70 (95% CI: 0.27–1.76) to 4.09 (95% CI: 2.03–8.25),
depending on the criteria used. The mean age and diagnostic criteria of MetS were identified
as sources of heterogeneity in the estimated odds ratios between studies (P<0.05).
Conclusions
According to the high prevalence of MetS in RA patients, and high risk of MetS, measuring
metabolic syndrome in RA patients is strongly recommended. Furthermore, as high waist
circumference (WC) is the most common metabolic syndrome component, more attention
must be paid to nutrition and weight loss among those with RA.
Introduction
Metabolic syndrome (MetS) is comprised of a group of risk factors for type 2 diabetes and car-
diovascular diseases, including insulin resistance, abdominal obesity, dyslipidemia, blood pres-
sure, and impaired fasting glucose[1]. The most common clinical manifestations of MetS
include: abdominal obesity, hypertriglyceridaemia, reduced high-density lipoprotein choles-
terol (HDL-C), hyperglycaemia, and high blood pressure (BP)[2]. MetS is responsible for a
three-fold increase in the risk of atherosclerotic cardiovascular diseases (CVDs) and increased
mortality from CVD, as well as all-causes, compared to the general population [3]. MetS is also
associated with a fourfold increased relative risk of developing diabetes [4, 5]. There are eight
commonly used definitions for MetS, but the National Cholesterol Education Programme-
Adult Treatment Panel III (NCEP ATP III) and the International Diabetes Federation (IDF)
definitions are the most commonly used [6]. These definitions have many similarities, but they
differ on several components and on the cut-off points used (Table 1).
Therefore, although we could expect slight differences in prevalence rates, according to the
criteria used in each study, genetic and geographical differences may also contribute to differ-
ences in the rates of MetS. For example, using the ATP III definition, Ford et al. reported the
prevalence rate of metabolic syndrome in the USA to be 34.3% [3], while Tillin et al. reported
the age-adjusted rates were 18.4% for men and 14.4% for women among Europeans, 28.8% for
men and 31.8% for women in South Asians, and 15.5% for men and 23.4% for women in Afri-
can-Caribbeans. Further, the prevalence rate was reported to be 15.7% in Taiwan, using the
same criteria[7, 8].
Rheumatoid arthritis (RA) is a chronic inflammatory disorder of unknown etiology [9] that
has a prevalence rate of approximately 0.5 to 1% [10]. Rheumatoid arthritis and metabolic syn-
drome are considered to be diseases with common traits that can increase the risk of cardio-
vascular disease[11], with previous research showing an association between the two[12].
Higher frequencies of insulin resistance and MetS have been reported in patients with RA [12,
13], with the frequency of MetS in RA patients ranging from 14 to 56% [14]. This variation can
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be explained by differences in the definition of MetS, along with differences in ethnicity, geo-
graphic area, study design, and study population. However, although many studies have
reported a higher prevalence of MetS among RA patients, compared to the general population
[15, 16], a number of studies have reported a higher prevalence of MetS in the healthy controls
[2].
Research measuring the prevalence of MetS in RA patients has resulted in a wide range of
estimates across the world. In addition, research measuring the prevalence of metabolic syn-
drome using a large sample size is rare. Furthermore, there have been very few meta-analyses
on the prevalence of MetS in patients with rheumatoid arthritis [11]. Therefore, the present
study aimed to: 1) determine the prevalence of MetS, and its components, in RA patients
across the world 2) update the odds ratio of MetS in RA patients, compared to healthy con-
trols, using a comprehensive systematic review and meta-analysis.
Methods
Search strategy and study selection
The current systematic review and meta-analysis was conducted according to PRISMA guide-
lines [17]. A systematic review was undertaken of English-language medical literature
Table 1. Summary of the MetS definitions.
Definitions WHO NCEP-ATP III IDF EGIR AACE AHA/NHLBI ATP III JS 2009
Number of
Criteria
Two or more of: Three or more
of:
Two or more
of
Two or
more of:
Obesity and
two or more of:
Three or more
of:
Three or more
of:
Three or more
of:
Obesity BMI > 30 and/or
WHR > 0.9
(men),
WHR > 0.85
(women)
WC 102 cm
(men), WC 88
cm (women
WC 94 cm
men,
WC 80 cm
women
WC 94
cm (men,
WC80
cm
(women)
WC 102 cm
(men),
WC 88 cm
(women
BMI 30 kg/m2 WC 102 cm
(men),
WC 88 cm
(women
Population- and
country-specific
definitions
Blood
pressure
mmhg
 140/90  130/85 or
treatment
130/85 or
treatment
 140/90  130/85 or
treatment
130/85 mmHg
or previous
hypertension
diagnosis
 130/85 or
treatment
 130/85 or
treatment
Dyslipidmia:
HDL-C  35 mg/dL (0.9
mmol/L) in men
or 39 mg/dL
( 1.0 mmol/L)
in women
 40 mg/dL
(1.03 mol/L) in
men, 50 mg/
dL (1.29 mmol/
L) in women, or
treatment
 40 mg/dL
(1.03 mol/L)
in men, 50
mg/dL (1.29
mmol/L) in
women, or
treatment
 39 mg/
dL (1.0
mmol/L) or
treatment
 40 mg/dL
(1.03 mol/L) in
men, 50 mg/
dL (1.29 mmol/
L) in women, or
treatment
 40 mg/dL
(1.03 mol/L) in
men, 50 mg/
dL (1.29 mmol/L)
in women
 40 mg/dL
(1.03 mol/L) in
men, 50
mg/dL (1.29
mmol/L) in
women
 40 mg/dL
(1.03 mol/L) in
men, 50 mg/
dL (1.29 mmol/
L) in women, or
treatment
Triglycerides 178 mg/dL(2.0
mmol/L) or
treatment
150 mg/dL
(1.7 mmol/L) or
treatment
150 mg/dL
(1.7 mmol/L)
or treatment
150 mg/
dL (1.7
mmol/L)
150 mg/dL
(1.7 mmol/L) or
treatment
150 mg/dL (1.7
mmol/L) or
treatment
150 mg/dL
(1.7 mmol/L)
150 mg/dL
(1.7 mmol/L) or
treatment
Glucose
Intolerance or
Fasting
Plasma
Glucose
110 mg/dL
(6.1 mmol/l),
DM, IGT, IR
100 mg/dL
(5.6 mmol/L) or
T2D
100 mg/dL
(5.6 mmol/L)
or T2D
110 mg/
dL (6.1
mmol/L)
110 mg/dL
(6.1 mmol/l), or
treatment
100 mg/dL (5.6
mmol/L) or T2D
110 mg/dL
(6.1 mmol/L)
100 mg/dL
(5.6 mmol/L) or
T2D
BMI = body mass index; JC = Joint Consensus; DM = diabetes mellitus; EGIR = European Group against Insulin Resistance; HDL-C = high-density
lipoprotein cholesterol; IDF = International Diabetes Federation; IGT = impaired glucose tolerance; IR = insulin resistance; NCEP ATPIII = National
Cholesterol Education Program Adult Treatment Panel; AACE = American Association of Clinical Endocrinologists; AHA/NHLBI = The American Heart
Association / National Heart, Lung, and Blood Institute; JS = Joint Statement; T2 D, type II diabetes mellitus; WC = waist circumference; WHO = World
Health Organization; WHR = waist hip ratio.
https://doi.org/10.1371/journal.pone.0170361.t001
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published between January 2000 and August 2016 to identify scientific papers reporting the
prevalence and risk of metabolic syndrome and its components (i.e., waist circumference—
WC, blood pressure—BP, high-density lipoprotein cholesterol -HDL-C, Triglycerides—TG,
fasting blood sugar—FBS) among rheumatoid arthritis patients.
International databases, including: the Web of Science, Medline, Scopus, Embase, CABI,
CINAHL, DOAJ, Index Medicus for Eastern Mediterranean Region-IMEMR and Google
Scholar were searched using the following medical subject headings (MeSH): “Metabolic Syn-
drome”, “Dysmetabolic Syndrome”, “Cardiovascular Syndrome”, and “Insulin Resistance Syn-
drome”, combined with “Rheumatoid Arthritis”, “Prevalence”, “Odds Ratio”, “Comparative
Cross-sectional Studies” and “case-control studies”. The search strategy for Medline was devel-
oped first and then adapted for the remaining databases. More detailed information regarding
the search strategy is presented in Box 1. The grey literature were searched using Google
Scholar, as recommended [18], using the abovementioned search strategy. An expert in this
field was also consulted to identify additional papers.
All publications were categorized using Endnote X6. The title and abstract of identified
publications were systematically screened and full texts were obtained for those which passed
the initial screening. All full text publications were then independently evaluated by two
reviewers (SS and JH) for inclusion in the review. Disagreements between the reviewers were
resolved by consensus using a third expert (MN). In this study, blinding and task separation
were also applied to study selection.
Box 1. Search strategy for MEDLINE (MeSH, Medical Subject
Headings).
1: Metabolic Syndrome [Text Word] OR Metabolic Syndrome [MeSH Terms]
2: Dysmetabolic Syndrome [Text Word] OR Dysmetabolic Syndrome [MeSH Terms]
3: Cardiovascular Syndrome [Text Word] OR Cardiovascular Syndrome [MeSH
Terms]
4: Insulin Resistance Syndrome [Text Word] OR Insulin Resistance Syndrome
[MeSH Terms]
5: 1 OR 2 OR 3 OR 4
6: Rheumatoid Arthritis [Text Word] OR Rheumatoid Arthritis [MeSH Terms]
7: 5 AND 6
8: Prevalence [Text Word] OR Prevalence [MeSH Terms]
9: Odds Ratio [Text Word] OR Odds Ratio [MeSH Terms]
10: Risk Ratio [Text Word] OR Risk Ratio [MeSH Terms]
11: Cross-Product Ratio [Text Word] OR Cross-Product Ratio [MeSH Terms]
12: 8 OR 9 OR 10 OR 11
13: Cross-sectional Studies [Text Word] OR Cross-sectional Studies [MeSH Terms]
14: Case-Control Studies [Text Word] OR Case-Control Studies [MeSH Terms]
15: Comparative cross-sectional Studies [Text Word] OR Comparative cross-sec-
tional Studies [MeSH Terms]
16: 13 OR 14 OR 15
17: 7 AND 12 AND 16
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All English language observational (cross-sectional and comparative cross-sectional) stud-
ies on the prevalence of metabolic syndrome were included in the current study if they clearly
described the date of data collection and study location, used appropriate sampling strategies,
and conducted appropriate statistical analyses. Case studies and letters to the editor were
excluded, along with systematic reviews or meta-analyses. Lastly, studies undertaken on
patients with other disorders were also excluded.
Data extraction and quality assessment
Study characteristics (first author’s name, date of publication, and country of origin), partici-
pant characteristics (gender, age, and sample size), and MetS prevalence (based on the differ-
ent criteria) were extracted using the full text reviews. The quality of each included study was
also assessed using the STROBE checklist [19].
Statistical analysis
All statistical analyses were undertaken using Review Manager (RevMan) Version 5.3. (Copen-
hagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The prevalence of
metabolic syndrome, and its five components, among rheumatoid arthritis patients were
pooled using a random-effects model and presented in a forest plot. The odds ratios for meta-
bolic syndrome in rheumatoid arthritis patients, based upon the different diagnostic criteria,
in comparative cross-sectional studies were also pooled using a random-effects model and pre-
sented in a forest plot. Statistical heterogeneity was assessed using the I2 index and a random-
effects model was used when the I2 index was > 0.6. Stata software version 13 (Stata Corp, Col-
lege Station, TX, USA) was used to determine which factors were responsible for any observed
heterogeneity using meta-regression. Publication bias, with regards to the ORs between MetS
and RA was assessed using a Funnel plot and Begg’s correlation test [20].
Results
After removing duplicates, our primary search found 237 relevant articles. Following the
exclusion of all non-eligible studies a total of 70 cross-sectional studies and 43 comparative
cross-sectional studies, from 25 countries, were retained to estimate the prevalence and risk of
metabolic syndrome among RA patients. The details of our study selection method are shown
in Fig 1. The majority of the studies reporting MetS prevalence (55 studies) included both
male and female patients who were aged>18 years. The lowest and highest prevalence of MetS
in rheumatoid arthritis patients reported were 10.6% and 55.5%, respectively. More detailed
information about each included studies can be found in Table 2.
The estimated pooled prevalence, with 95% confidence interval (the diamond below the
graph shows the pooled prevalence and the horizontal lines define the reported 95% confi-
dence interval in each study) are presented in graphs by gender and by MetS definition.
Total MetS prevalence in RA patients by gender
Using a random effects model, the estimated worldwide prevalence rate of MetS among RA
patients was 30.65% (95% CI: 27.87–33.43) (Fig 2). In addition, information on the prevalence
of MetS by gender was available from 19 studies for males and 30 for females. The prevalence
rates among males was 31.94% (95% CI: 24.37–39.51) and for females this was 33.03% (95%
CI: 28.09–37.97) (Figs 3 and 4).
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MetS prevalence in RA patients by criteria/definition
The pooled MetS prevalence rates for the eight definitions are: WHO—19.96% (95% CI:
17.12–22.81), NCEP/ATP III—31.55% (95% CI: 27.95–35.15), IDF—32.84% (95% CI: 24.98–
40.71), EGIR—14.32% (95% CI: 10.59–18.05), ACCE—24.6% (95% CI: 19.29–30.91), AHA/
NHBI—31.39% (95% CI: 20.61–42.17), ATP III—37.83% (95% CI: 31.05–44.61) and JS 2009–
27.54 (95% CI: 17.85–37.24) (Fig 5).
Fig 1. Flow diagram of the study selection process.
https://doi.org/10.1371/journal.pone.0170361.g001
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Table 2. Worldwide prevalence (95% CI) of metabolic syndrome in rheumatoid arthritis patients.
First Author Country Criteria DOP Age
Range
Mean
Age
Gender N. of RA Patients Prevalence of MetS in
RA Patients (%)
Reference
Total Male Female Total Male Female
Lee SH Korea AHA/NHLBI 2016 12 63.6 Both 598 110 488 36.4 34.5 36.9 [37]
Hugo M France IDF 2016 18–75 57.6 Both 57 15 42 24.0 25.0 24.0 [38]
Zafar ZA Pakistan NCEP-ATP III 2016 20–60 43.8 Both 384 97 277 31.3 18.5 35.5 [35]
Oliveira BMGB Brazil NCEP-ATP III 2016 - 55.5 Female 107 - 107 51.4 - 51.4 [24]
Oliveira BMGB Brazil IDF 2016 - 55.5 Female 107 - 107 53.4 - 53.4 [24]
Muller R Estonia NCEP-ATP III 2016 - 51.6 Both 91 66 25 35 [33]
Dihingia P India NCEP-ATP III 2016 >12 41.5 Both 72 6 66 16.7 [39]
Ghazaly AHAH Egypt ATP III 2015 18 40.7 Both 80 13 67 50.0 53.8 49.2 [40]
Salamon L Croatia ATP III 2015 52–68 59 Both 583 100 483 43.1 40.0 43.7 [41]
Tanayakom P Thailand NCEP-ATP III 2015 - 59 Both 267 31 236 16.1 12.9 16.5 [42]
Parra-Salcedo F Mexico AHA/NHLBI 2015 - 38.1 Both 160 18 142 28.0 [43]
Parra-Salcedo F Mexico IDF 2015 - 38.1 Both 160 18 142 18.0 [43]
Parra-Salcedo F Mexico NCEP-ATP III 2015 - 38.1 Both 160 18 142 24.0 [43]
Craciun L Romania IDF-AHA 2014 32–79 55.2 Both 51 7 77 19.0 10.52 82.47 [23]
Craciun L Romania NCEP-ATP III 2014 32–79 55.2 Both 51 7 77 23.0 [23]
Craciun L Romania IDF 2014 32–79 55.2 Both 51 7 77 18.0 [23]
Craciun L Romania AHA 2014 32–79 55.2 Both 51 7 77 14.0 [23]
Bilecik NA Turkey IDF 2014 24–65 52.0 Female 100 - 100 33.0 - 33.0 [44]
Bilecik NA Turkey NCEP-ATP III 2014 24–65 52.0 Female 100 - 100 27.0 - 27.0 [44]
O¨ zmen M Turkey NCEP-ATP III 2014 - 51.0 Both 52 15 37 17.30 [45]
O¨ zmen M Turkey WHO 2014 - 51.0 Both 52 15 37 28.80 [45]
Kumar BS India IDF 2014 18 46.0 Both 54 6 48 29.0 [46]
Kumar BS India NCEP-ATP III 2014 18 46.0 Both 54 6 48 31.0 [46]
Abourazzak FE Morocco IDF 2014 >16 49.0 Both 179 22 157 30.7 [26]
Abourazzak FE Morocco NCEP-ATP III 2014 >16 49.0 Both 179 22 157 29.0 [26]
Abourazzak FE Morocco AACE 2003 2014 >16 49.0 Both 179 22 157 24.6 [26]
Salinas MJH Argentina ATP III 2013 - 55.5 Both 409 69 340 30.0 62.0 23.8 [47]
Salinas MJH Argentina IDF 2013 - 55.5 Both 409 69 340 35.0 [47]
Abdul-Qahar Iraq NCEP-ATP III 2013 - 46.9 Both 203 41 162 51.2 12.0 92.0 [48]
Rostam S Morocco NCEP-ATP III-
2004
2013 - 49.0 Both 120 10 110 30.8 10.0 32.7 [49]
Rostam S Morocco NCEP-ATP III-
2001
2013 - 49.0 Both 120 10 110 24.6 [49]
Rostam S Morocco WHO 2013 - 49.0 Both 120 10 110 20.0 [49]
Rostam S Morocco IDF 2013 - 49.0 Both 120 10 110 48.6 [49]
Rostam S Morocco EGIR 2013 - 49.0 Both 120 10 110 18.0 [49]
Rostam S Morocco JC 2009 2013 - 49.0 Both 120 10 110 32.3 [49]
Lee SG Korea NCEP-ATP III 2013 22–76 50.6 Female 84 - 84 19.0 - 19.0 [34]
Ormseth MJ USA ATP III 2013 18 54.0 Both 162 18 144 36.0 [50]
Karakoc Turkey IDF 2012 - 49.8 Both 54 7 47 42.6 [51]
Manka V Slovakia IDF 2012 18 58.8 Both 87 4 83 48.3 [52]
Manka V Slovakia NCEP-ATP III 2012 18 58.8 Both 87 4 83 44.8 [52]
Manka V Slovakia AHA/NHLBI 2012 18 58.8 Both 87 4 83 47.1 [52]
Cunha VR Da Brazil NCEP-ATP III 2012 18 56.8 Both 283 50 233 39.2 [53]
Goshayeshi L Iran NCEP-ATP III 2012 - 45.5 Both 120 14 106 45.2 [21]
Bkaer JF USA IDF 2012 18–85 49.5 Both 499 83 416 10.6 [54]
(Continued )
Worldwide prevalence and risk of metabolic syndrome in rheumatoid arthritis patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0170361 March 23, 2017 7 / 21
MetS prevalence in rheumatoid arthritis patients by MetS component
The MetS components of FBS, HDL-C, BP, Triglyceride and Waist Circumstance (WC) were
reported by 26, 22, 29, 19 and 24 studies, respectively. The pooled MetS prevalence rates, by
component, were: FBS—19.47% (95% CI: 15.69–23.25), HDL—41.78% (95% CI: 28.73–54.84),
BP—48.65% (95% CI: 41.03–56.26), Triglyceride—28.43% (95% CI: 22.3–34.57) and WC—
52.63 (95% CI: 43.76–61.5) (S 1–5 Appendix).
Risk of MetS in rheumatoid arthritis patients by criteria/definition
In this section the prevalence of MetS in RA patients and among healthy controls were com-
pared (Table 3). The pooled estimates identified a significant positive association between
rheumatoid arthritis and the risk of MetS (OR = 1.44; 95% CI: 1.20–1.74). The odds ratios for
Table 2. (Continued)
First Author Country Criteria DOP Age
Range
Mean
Age
Gender N. of RA Patients Prevalence of MetS in
RA Patients (%)
Reference
Total Male Female Total Male Female
Crowson CS USA NCEP-ATP III 2011 18 58.8 Both 232 58 174 33.0 36.0 32.0 [31]
Sahaberi M Iran IDF 2011 - 45.5 Both 120 14 106 30.8 28.6 41.5 [55]
Sahaberi M Iran NCEP-ATP III 2011 - 45.5 Both 120 14 106 45.2 28.6 37.7 [55]
Karimi M Iran NCEP 2011 18 48.3 Female 92 - 92 27.2 - 27.2 [22]
Karimi M Iran WHO 2011 18 48.3 Female 92 - 92 19.6 - 19.6 [22]
Mok CC Hong Kong JS 2009 2011 18 53.3 Both 699 133 566 20.0 [56]
Dao HH Vietnam IDF 2010 26–73 56.3 Female 105 - 105 40.9 - 40.9 [57]
Dao HH Vietnam NCEP-ATP III
2004
2010 26–73 56.3 Female 105 - 105 32.4 - 32.4 [57]
Dao HH Vietnam NCEP-ATP III
2001
2010 26–73 56.3 Female 105 - 105 24.7 - 24.7 [57]
Dao HH Vietnam JS 2009 2010 26–73 56.3 Female 105 - 105 32.4 - 32.4 [57]
Dao HH Vietnam WHO 2010 26–73 56.3 Female 105 - 105 19.0 - 19.0 [57]
Dao HH Vietnam EGIR 2010 26–73 56.3 Female 105 - 105 16.2 - 16.2 [57]
Raterman H G Netherlands NCEP 2010 50–75 62.1 Both 236 79 157 19.9 [58]
Solomon A South
Africa
NCEP-ATP III 2010 - 27.2 Both 291 32 259 31.3 [59]
Solomon B South
Africa
NCEP-ATP III 2010 - 27.2 Both 335 65 270 20.3 [59]
Giles J USA NCEP-ATP III 2010 45–84 61 Both 131 51 80 36.0 [60]
Santos MJ Portugal ATP III 2010 18 49.2 Female 98 98 25.5 [61]
Toms TE UK IDF 2009 55.5–69.6 63.1 Both 387 105 282 45.3 52.7 42.6 [25]
Toms TE UK NCEP-ATP III
2004
2009 55.5–69.6 63.1 Both 387 105 282 40.1 42.5 39.2 [25]
Toms TE UK NCEP-ATP III
2001
2009 55.5–69.6 63.1 Both 387 105 282 38.3 40.0 37.7 [25]
Toms TE UK WHO 2009 55.5–69.6 63.1 Both 387 105 282 19.4 25.5 17.2 [25]
Toms TE UK EGIR 2009 55.5–69.6 63.1 Both 387 105 282 12.1 22.6 8.2 [25]
Chung CP USA WHO 2008 18 59 Both 66 18 48 42.0 [29]
Zonana-Nacach
A
Mexico NCEP-ATP III 2008 - 42.9 Both 107 18.7 [30]
Karvounaris SA Greece ATP III 2007 18 63.0 Both 200 53 147 44.0 39.6 45.6 [32]
Montagna G La Italy NCEP-ATP III 2007 - 53.8 Both 45 3 42 55.5 [62]
https://doi.org/10.1371/journal.pone.0170361.t002
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Fig 2. Forest plot of MetS prevalence in RA Patients.
https://doi.org/10.1371/journal.pone.0170361.g002
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MetS in rheumatoid arthritis patients, according to the definition used, were: WHO—
OR = 1.45 (95% CI: 0.9–2.33), NCEP/ATP III—OR = 1.52 (95% CI: 1.12–2.06), IDF—
OR = 1.52 (95% CI: 0.84–2.77), EGIR—OR = 1.65 (95% CI: 0.95–2.87), ACCE—OR = 4.09
(95% CI: 2.03–8.25), AHA/NHBI—OR = 0.7 (95% CI: 0.27–1.76), ATP III—OR = 1.22 (95%
CI: 0.71–2.1), and JS 2009—OR = 1.58 (95% CI: 0.84–2.94) (Fig 6).
Publication bias
In order to assess publication bias in relation to the OR for MetS and RA, funnel plots and
Begg’s correlation were used. These found no evidence of any publication bias (Fig 7).
Meta-regression
To assess the sources of heterogeneity, four variables were included in a univariable meta-
regression. Our results indicated that the study date (P = 0.60) and country (P = 0.38) were not
responsible for the heterogeneity in the ORs for MetS in RA patients, compared to healthy con-
trols, but mean age (P = 0.03) and diagnostic criteria (P = 0.04) could be considered sources of
heterogeneity. Hence, subgroup analysis was undertaken based upon the diagnostic criteria.
Discussion
The present study found a MetS prevalence of 30.65% among RA patients, but this rate ranged
from 14.32% to 37.83%, depending upon the MetS definition used. The relatively high degree
Fig 3. Forest plot of MetS prevalence among male RA Patients.
https://doi.org/10.1371/journal.pone.0170361.g003
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of variability in MetS prevalence, according to the MetS definition used, is clearly a substantial
issue that permeates the literature on this topic. For example, research in Asia has reported the
prevalence of MetS to be 45.2% among RA patients using the NCEP-ATP III criteria [21] and
19.6% when using the WHO definition[22]. In Europe the prevalence rates reported, accord-
ing to criteria used were: AHA (27.4%), IDF (35.2%), IDF-AHA (37.2%) and NCEP-ATP III
(23.0%)[23]. Furthermore, based on the NCE-P-ATP III criteria, Oliveira et al. found that the
prevalence of MetS among RA patients in South American was 51.4%, but using the IDF crite-
ria this proportion was 53.4% [24]. Much larger differences have been reported in research
from the UK, with MetS prevalence ranging from 8.2% to 42.6% [25], depending upon the def-
inition used. Moreover, in a cross-sectional study which used three definitions (NCEP-ATP
Fig 4. Forest plot of MetS prevalence among female RA Patients.
https://doi.org/10.1371/journal.pone.0170361.g004
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Fig 5. Forest plot of MetS prevalence among RA Patients by definition/criteria.
https://doi.org/10.1371/journal.pone.0170361.g005
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III, IDF and AACE) the prevalence of MetS in RA patients varied from 24.6 to 30.7% [26].
Finally, the results of a case- control study in 2013 showed that the frequency of MetS in RA
patients and the control group were 30% versus 39% (respectively) when using the ATP III def-
inition and 35% versus 40% (respectively) when using the IDF [27] definition.
Fig 6. Forest plot of MetS risk among RA patients by definition/criteria.
https://doi.org/10.1371/journal.pone.0170361.g006
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Therefore, it appears that some of the variation in the prevalence reported are to do with i)
a lack of definition clarity, with many different criteria in the existing definitions, ii) different
and multiple phenotypes included in each definition of MetS, and iii) the lack of consistency
in the number of components required by each definition.
However, prevalence rates also vary widely even when comparing studies that have used the
same criteria. For example, using the NCE/ATP definition, Dessein et al. reported a MetS prev-
alence of 19% among 74 RA patients [28], while a separate study using the same definition
reported a prevalence rate of 42% in those with long standing RA and 30% in those recently
diagnosed with RA[29]. Further, in a study of 107 female RA patients a MetS prevalence of
18.7% [30] was reported, but using the same definition Crowson et al. reported the prevalence
to be 33%[31]. Therefore, it is likely that other factors related to the characteristics of the study
population, such as: genetic, ethnic, cultural, demographic, socioeconomic and clinical factors,
also affect the prevalence. Thus, studies conducted using different populations are critical in
order to identify other factors related to MetS.
In this study the risk of MetS in RA patients was 45% higher than that in the healthy control
group (OR = 1.45; 95% CI: 1.20–1.75). The OR found in the present study is considerably
higher than that reported in a meta-analysis of 12 studies in 2013, which reported an OR of
1.24 (95% CI, 1.03–1.50) [11]. Furthermore, Karvounaris et al. found prevalence of MetS to be
similar in RA patients (44%) to their control population (41%), but they also found a relation-
ship between disease activity and the presence of MetS [32]. It is also worth mentioning that
several studies have not reported any association between RA and MetS [33, 34].
When we assessed the individual components of MetS (FBS, HDL, BP, Triglyceride, WC), a
high WC had the highest prevalence, while the lowest prevalence was high FBS. These findings
are consistent with a cross-sectional study by Zafar et al., which found that high FBS (21.9%)
was the least prevalent component, while a high WC (46.1%) was the most prevalent compo-
nent[35]. Furthermore, a study of 200 rheumatoid arthritis outpatients reported that the preva-
lence of a high WC was 74.8% in female patients and 60.4% in male patients, while the
prevalence of high FBS were 30.6% and 26.4% in female and male patients, respectively [32].
Fig 7. Funnel plot of MetS risk among RA Patients by definition/criteria.
https://doi.org/10.1371/journal.pone.0170361.g007
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In another study, blood pressure, hypoglycemia and HDL had prevalence’s of 35.9%, 22.95
and 68.9%, respectively [36]. Therefore, it seems that in most studies a high WC is the most
prevalent MetS component and targeting preventative measures at this may considerably
reduce the risk of developing MetS.
Advantages
The present study has a number of advantages over the previous meta-analysis, including:
1) All of the published studies were included in this meta-analysis. 2) The prevalence of meta-
bolic syndrome was investigated in RA patients from across the world. 3) This study reported
the prevalence of MetS in RA patients based upon eight separate definitions. 4) This paper
included both comparative cross-sectional and cross-sectional studies. 5) The odds ratio for
metabolic syndrome was pooled across a large number of studies.
Limitations
1) Several countries have not assessed the prevalence of MetS in RA patients and therefore
data from those countries could not be presented in this study. 2) The crude (unadjusted)
odds ratio for MetS in RA patients was reported, as different studies used different set(s) of
confounders.
Conclusion
The prevalence of MetS in RA patients was relatively high, but did not vary significantly by
gender. According to the high prevalence of MetS in RA patients and the high risk of it, moni-
toring and testing for metabolic syndrome in these patients is clearly recommended. As the
most important component of metabolic syndrome was found to be a high WC, it is clearly
important to pay more attention to patient nutrition and weight loss. Finally, mean age and
the diagnostic criteria used to diagnose MetS were identified as sources of heterogeneity in the
estimated risk of MetS.
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